-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O9TpgEsPSVHE7AFtgQzPiFMmfUEUrL1ZIT58UAqlDhVo+g9qy+Vbhhak3sm941be cD6K5k/59Ql3quhP8KYYjg== 0001238921-07-000006.txt : 20070604 0001238921-07-000006.hdr.sgml : 20070604 20070604180804 ACCESSION NUMBER: 0001238921-07-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070604 FILED AS OF DATE: 20070604 DATE AS OF CHANGE: 20070604 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSITE INC CENTRAL INDEX KEY: 0000834306 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330288606 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194554808 MAIL ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BIOSITE DIAGNOSTICS INC DATE OF NAME CHANGE: 19960710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIBBERD CHRISTOPHER R CENTRAL INDEX KEY: 0001238921 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21873 FILM NUMBER: 07898796 BUSINESS ADDRESS: STREET 1: C/O BIOSITE INC STREET 2: 11030 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584554808 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2007-06-04 0 0000834306 BIOSITE INC BSTE 0001238921 HIBBERD CHRISTOPHER R BIOSITE INCORPORATED 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 0 1 0 1 Senior Vice President Corpo Senior Vice President Corpo Common Stock 2007-06-04 4 M 0 40 31.625 A 2359 D Common Stock 2007-06-04 4 S 0 40 92.05 D 2319 D Common Stock 9075 I by Trust Non-Qualified Stock Option (right to buy) 31.625 2007-06-04 4 M 0 40 92.05 D 2000-06-02 2010-06-02 Common Stock 40 14745 D Option vests daily over a four-year period commencing on the date of grant, except that no options are exercisable for the first six months after the date of grant. By: Robyn Shutak For: Chris R. Hibberd 2007-06-04 -----END PRIVACY-ENHANCED MESSAGE-----